Actually as I think about it, the first one or two years of real sales might go up by more than double, as new centres that have trialled the patch start making multiple re-orders. So we might go to $10m more quickly, even without steady increases in the number of centres.
My thinking is this: If the vaccine business gets reasonable success it will support the share price. If it doesn't and the share price drops, then there will perhaps be an opportunity to top up on AHZ before the Cardiocel sales figures show significant improvement. Doubling sales every year would be a top tier achievement.
And the final sweetener would be any news on the stem cell collaboration.
A new beginning..., page-23
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.49 |
Change
0.490(4.08%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $12.11 | $12.49 | $11.50 | $155.8K | 13.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 175 | $11.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.49 | 77 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |